Log in

Intersect ENT Stock Forecast, Price & News

+0.06 (+0.30 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $20.25
50-Day Range
MA: $17.49
52-Week Range
Now: $20.25
Volume172,900 shs
Average Volume571,150 shs
Market Capitalization$662.56 million
P/E RatioN/A
Dividend YieldN/A
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Read More
Intersect ENT logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:XENT



Sales & Book Value

Annual Sales$109.14 million
Book Value$3.75 per share


Net Income$-42,990,000.00


Market Cap$662.56 million
Next Earnings Date2/22/2021 (Estimated)
+0.06 (+0.30 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

How has Intersect ENT's stock price been impacted by Coronavirus?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XENT stock has decreased by 5.8% and is now trading at $20.25.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Intersect ENT?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intersect ENT

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Intersect ENT

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Thursday, November, 5th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.10. The medical equipment provider had revenue of $22.72 million for the quarter, compared to analysts' expectations of $21.78 million. Intersect ENT had a negative net margin of 71.96% and a negative return on equity of 55.81%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.41) EPS.
View Intersect ENT's earnings history

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, November, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $26.991-28.579 million, compared to the consensus revenue estimate of $29 million.

What price target have analysts set for XENT?

8 Wall Street analysts have issued 12-month target prices for Intersect ENT's shares. Their forecasts range from $10.00 to $32.00. On average, they expect Intersect ENT's stock price to reach $20.57 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts' price targets for Intersect ENT

Are investors shorting Intersect ENT?

Intersect ENT saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,400,000 shares, an increase of 34.6% from the October 15th total of 1,040,000 shares. Based on an average daily trading volume, of 240,600 shares, the days-to-cover ratio is currently 5.8 days. Currently, 4.5% of the shares of the company are sold short.
View Intersect ENT's Short Interest

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Mr. Thomas A. West, Pres, CEO & Director (Age 56, Pay $435.89k)
  • Mr. Richard A. Meier, Exec. VP & CFO (Age 60, Pay $182.88k)
  • Ms. Gwen R. Carscadden, Chief People Officer (Age 59, Pay $363.82k)
  • Ms. Jeryl Lynn Hilleman, Advisor (Age 62, Pay $549.49k)
  • Ms. Christine R. Kowalski, Exec. VP & COO (Age 62)
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 56)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.10%), First Light Asset Management LLC (3.63%), Jennison Associates LLC (3.08%), Neuberger Berman Group LLC (2.82%), Great Point Partners LLC (2.29%) and State Street Corp (2.16%). Company insiders that own Intersect ENT stock include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Robert H Binney, Jr, Susan P Stimson and Thomas A West.
View institutional ownership trends for Intersect ENT

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, AQR Capital Management LLC, BlackRock Inc., Aigen Investment Management LP, Wells Fargo & Company MN, Neuberger Berman Group LLC, Morgan Stanley, and Mackay Shields LLC.
View insider buying and selling activity for Intersect ENT

Which institutional investors are buying Intersect ENT stock?

XENT stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Jennison Associates LLC, Assenagon Asset Management S.A., Voloridge Investment Management LLC, ExodusPoint Capital Management LP, Jackson Creek Investment Advisors LLC, Sei Investments Co., and Gabelli Funds LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $20.25.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $662.56 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 402 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.